Argentum Infection Prevention & Control Announcements

U.S. health regulators cleared use of retooled Covid-19 vaccines that target the latest versions of Omicron, in preparation for a fall booster campaign that could start within days.

Fall is a time for change. The leaves turn from green to vibrant shades of yellow, orange, and red. The air turns cooler and crispier. And, unfortunately, the risk of contracting COVID and influenza increases as people spend more time indoors. It's important to take precautions against these illnesses, especially for seniors living in senior living communities.

Infection prevention and control is one of the most important aspects of senior living. As our population ages, the risk of infection increases, so it is important to have systems in place that protect our residents from illnesses and keep them healthy.

We have certainly been impressed by the innovation and creativity that came from two years of societal upheaval and now we are at a point in time where we, as an industry, can move forward. With new pathogens constantly emerging, Argentum is thrilled to announce that we are expanding the COVID-19 blog to include some of the latest research, news and advances in infection prevention and control.

Please share this blog with colleagues who may be interested in receiving infection prevention and control news and resources in their inboxes. Thanks for reading, and stay safe!

The Biden administration said it would spend $1.74 billion to buy 66 million doses of Moderna Inc.’s updated Covid-19 vaccine, as well as the option to purchase up to 234 million additional doses, as part of a fall booster campaign.

The U.S. Centers for Disease Control (CDC) approved the COVID-19 vaccine from Maryland-based vaccine maker Novavax, unlocking the 3.2 million doses that the U.S. government has purchased from Novavax for widespread distribution.

Instead of keeping with COVID-19 vaccine boosters that target the original strain of SARS-CoV-2, an FDA advisory panel said this week that it favors reformulating the doses to also work against newer Omicron subtypes, reports the New York Times.

To the relief of many parents and caregivers, panels for the Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) have determined that the known and potential benefits of vaccinating children 6 months of age and older outweigh the known and potential risks in the pediatric populations authorized for use for use of the Moderna COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine. Vaccinations began this week.

The Food and Drug Administration (FDA) gave the green light on Tuesday, March 29 to a second coronavirus vaccine booster shot for people aged 50 and older in an effort to ward off another potential spike in infections due to a subvariant of omicron.

Drugmaker Moderna asked the Food and Drug Administration on Thursday to authorize a fourth shot of its Covid-19 vaccine as a booster dose for all adults.